This product is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), newly diagnosed high-risk metastatic endocrine therapy-sensitive prostate cancer (mHSPC), including patients who have not received endocrine therapy or have received endocrine therapy for no more than 3 months.
This product is combined with dexamethasone for adult patients with multiple myeloma who have received at least one therapy.
Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. (1) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. (1) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. (1) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy
1. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 2. Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy. 3. First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.
